{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=HL2283&max-answer.dateOfAnswer=2019-05-22", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?identifier=HL2283&max-answer.dateOfAnswer=2019-05-22", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=HL2283&_metadata=all&max-answer.dateOfAnswer=2019-05-22", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=HL2283&_page=0&max-answer.dateOfAnswer=2019-05-22", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=HL2283&max-answer.dateOfAnswer=2019-05-22", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=HL2283&max-answer.dateOfAnswer=2019-05-22", "items" : [{"_about" : "http://data.parliament.uk/resources/773568", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/773568/answer", "answerText" : {"_value" : "
Anyone suffering ill health deserves access to appropriate clinical investigation and care, and to be treated with dignity and respect. This is an important responsibility of doctors and other healthcare providers.<\/p>
The Medicines and Healthcare products Regulatory Agency takes every report of a suspected adverse reaction seriously and has closely evaluated the safety of the human papillomavirus vaccine since the vaccination programme was introduced in the United Kingdom in 2008. All reports, including any submitted by patients and their families, are kept under continual review to identify potential new risks.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"} } , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"} , "dateOfAnswer" : {"_value" : "2017-11-01", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-11-01T12:47:48.597Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-10-19", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what steps they are taking to ensure that the families of children believed to have suffered serious adverse reactions to human papilloma virus vaccinations are treated with the same levels of dignity and respect accorded to families whose children have other medical conditions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"} } , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"} ], "uin" : "HL2283"} , {"_about" : "http://data.parliament.uk/resources/600530", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/600530/answer", "answerText" : {"_value" : "
The Environment Agency (EA) has recently restructured its senior management team following a voluntary exit scheme and has filled all vacancies within the Energy Saving Opportunity Scheme (ESOS) senior team.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4284", "label" : {"_value" : "Biography information for Baroness Neville-Rolfe"} } , "answeringMemberPrinted" : {"_value" : "Baroness Neville-Rolfe"} , "dateOfAnswer" : {"_value" : "2016-10-19", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-10-19T13:26:25.943Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "201"} , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "date" : {"_value" : "2016-10-12", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Energy: Conservation"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what steps they are taking to fill senior management vacancies on the Energy Savings Opportunity Scheme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/621", "label" : {"_value" : "Biography information for Lord Moonie"} } , "tablingMemberPrinted" : [{"_value" : "Lord Moonie"} ], "uin" : "HL2283"} , {"_about" : "http://data.parliament.uk/resources/419210", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/419210/answer", "answerText" : {"_value" : "
Ensuring that the National Health Service is able to support the availability and use of effective medicines for cancers, including rare blood cancer, is a key priority.<\/p>
<\/p>
<\/p>
<\/p>
Cancer 52, an organisation which specifically represents patients with rarer cancers, was represented on the independent Cancer Taskforce. The Taskforce published its report, Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020<\/em>, in July, and made many recommendations relevant to rarer and blood cancers, focussing in particular on improving access to diagnostic testing, including fast, direct general practitioner access to key blood tests, and increasing patient access to the most advanced treatments. NHS England, Public Health England and other healthcare organisations are now considering the detail of the individual recommendations.<\/p> <\/p> <\/p> <\/p> Earlier in 2015, NHS England consulted on the principles and process by which it makes investment decisions in specialised services, which address the issue of rarity. The outcome of future investment decisions taken by NHS England will be published in accordance with the new process. NHS England\u2019s response to the consultation is attached, and can be found at:<\/p> <\/p> <\/p> <\/p>